Pitcairn’s Amicus Therapeutics FOLD Stock Holding History

Pitcairn’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-17,233	Closed	-$170K	–	618
2021 Q1	$170K	Buy	17,233 +254	+1%	+$3.93K	0.01%	594
2020 Q4	$392K	Buy	16,979 +605	+4%	+$12.4K	0.03%	362
2020 Q3	$231K	Buy	+16,374	New	+$239K	0.02%	450

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pitcairn's FOLD Position: Q2 2021 in Review

Pitcairn sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 17,233 shares — an estimated $170K sold.

Pitcairn first reported a position in FOLD in Q3 2020 and held it in 3 quarters. The position peaked at $392K in Q4 2020. 234 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

Pitcairn reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
Pitcairn sold 17,233 Amicus Therapeutics shares in Q2 2021, an estimated $170K.
Pitcairn first reported a position in Amicus Therapeutics in Q3 2020 and held it in 3 quarters.
Pitcairn's Amicus Therapeutics position peaked at $392K in Q4 2020.
234 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on Pitcairn's 13F filing for Q2 2021, filed 11 Aug 2021.